Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Testing a short PRAFAB questionnaire in Turkish for women with urinary incontinence

Official title: Evaluation of the Validity and Reliability of the Protection, Amount, Frequency, Compliance, Body Image (PRAFAB) Questionnaire in Women With Urinary Incontinence

Run by Afyonkarahisar Health Sciences University · NCT07339657 · Data updated 2026-11-12

This project will test whether a five-question PRAFAB questionnaire works well for Turkish-speaking women with urinary incontinence.

More Urinary Incontinence trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment63 (estimated)
SponsorAfyonkarahisar Health Sciences University
Academic / other
Locations1 site (Afyonkarahisar, Merkez)
StatusRecruiting
StartedOctober 15, 2024
Main results expectedAugust 15, 2026
Study endsAugust 15, 2026
Registry record updatedJanuary 14, 2026
Trial IDNCT07339657 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult Turkish-speaking women diagnosed with urinary incontinence by a urologist who are not pregnant or in the early postpartum period and who do not have excluded neurological, oncologic, or severe psychiatric conditions.

Probably not a fit

Women who are pregnant, in the early postpartum period, or who have bladder cancer, neurogenic bladder, recent urinary tract infection, severe cognitive impairment, or other excluded conditions are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers translated and culturally adapted the five-item PRAFAB questionnaire into Turkish and then performed validity and reliability analyses in women diagnosed with urinary incontinence. The project enrolled adult female outpatients at the Afyonkarahisar University health center who met inclusion and exclusion criteria. The team examined construct validity and test–retest reliability to see if the Turkish version produces consistent and meaningful scores. Results will determine if the PRAFAB-Turkish can capture both objective and subjective aspects of incontinence and its impact on quality of life.

Why it matters

Potential benefit: If successful, clinicians and researchers in Turkey will have a quick, validated Turkish tool to measure symptoms and quality-of-life impacts of urinary incontinence.

How similar studies have gone: PRAFAB has been validated in other languages and settings with generally good reliability and validity, so this translation follows established methods rather than testing a novel concept.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Being 18 years of age or older
* Have been diagnosed with urinary incontinence by a urologist
* Be female

Exclusion Criteria:

* Being pregnant,
* Being in the early postpartum period,
* Have been diagnosed with bladder cancer, diabetic nephropathy, a history of central nervous system damage, congenital urological disorders, urinary tract infection, neurogenic bladder, severe cognitive impairment, and severe psychiatric illness.

Where it's running

  • Emel Taşvuran Horata
    Afyonkarahisar, Merkez, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Emel Taşvuran Horata — Afyonkarahisar Sağlık Bİlimleri Üniversitesi
  • Study coordinator: Emel Taşvuran Horata
  • Email: ethorata@gmail.com
  • Phone: 05547759663

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.